Jiangsu Cowin Biotech Co. Ltd. A
Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and pr… Read more
Market Cap & Net Worth: Jiangsu Cowin Biotech Co. Ltd. A (688426)
Jiangsu Cowin Biotech Co. Ltd. A (SHG:688426) has a market capitalization of $349.11 Million (CN¥2.56 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #17908 globally and #4577 in its home market, demonstrating a 0.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Cowin Biotech Co. Ltd. A's stock price CN¥22.77 by its total outstanding shares 112493716 (112.49 Million).
Jiangsu Cowin Biotech Co. Ltd. A Market Cap History: 2022 to 2026
Jiangsu Cowin Biotech Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows change from $444.78 Million to $349.11 Million (-12.45% CAGR).
Jiangsu Cowin Biotech Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Cowin Biotech Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.48x
Jiangsu Cowin Biotech Co. Ltd. A's market cap is 3.48 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $444.78 Million | $521.60 Million | $159.26 Million | 0.85x | 2.79x |
| 2023 | $468.39 Million | $171.34 Million | -$84.41 Million | 2.73x | N/A |
| 2024 | $438.65 Million | $125.88 Million | -$157.21 Million | 3.48x | N/A |
Competitor Companies of 688426 by Market Capitalization
Companies near Jiangsu Cowin Biotech Co. Ltd. A in the global market cap rankings as of March 19, 2026.
Key companies related to Jiangsu Cowin Biotech Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Jiangsu Cowin Biotech Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, Jiangsu Cowin Biotech Co. Ltd. A's market cap moved from $444.78 Million to $ 349.11 Million, with a yearly change of -12.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥349.11 Million | -4.45% |
| 2025 | CN¥365.36 Million | -16.71% |
| 2024 | CN¥438.65 Million | -6.35% |
| 2023 | CN¥468.39 Million | +5.31% |
| 2022 | CN¥444.78 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Jiangsu Cowin Biotech Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $349.11 Million USD |
| MoneyControl | $349.11 Million USD |
| MarketWatch | $349.11 Million USD |
| marketcap.company | $349.11 Million USD |
| Reuters | $349.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.